Coherus Oncology (CHRS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual Shareholder Meeting scheduled virtually for May 27, 2026, at 1:30 pm PST.
Preliminary proxy filed to announce meeting and proposals; definitive proxy expected April 20, 2026.
Shareholders will receive proxy materials and are encouraged to vote on key proposals.
Voting matters and shareholder proposals
Proposal to reprice employee stock options with strike prices of $5 or more to the closing price on the meeting date.
Proposal requires a majority of votes cast "FOR" to pass.
Additional proposals may be included in the definitive proxy statement.
Board of directors and corporate governance
Directors, executive officers, and certain employees may participate in proxy solicitation.
Information about directors and executive officers, including their interests, is disclosed in the proxy statement.
Latest events from Coherus Oncology
- Shareholders will vote on director elections, auditor ratification, compensation, and equity plan changes.CHRS
Proxy filing9 Apr 2026 - Rapid oncology pipeline progress and strong LOQTORZI sales drive growth and pivotal trial plans.CHRS
The Citizens Life Sciences Conference 202610 Mar 2026 - LOQTORZI sales doubled, debt slashed, and key oncology trials advance toward 2026 data.CHRS
Q4 20259 Mar 2026 - Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth.CHRS
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Q2 revenue hit $65M, UDENYCA surged 60% YoY, divestitures boosted cash, and net loss shrank.CHRS
Q2 20242 Feb 2026 - Accelerating oncology growth with LOQTORZI, UDENYCA, and a robust, partner-driven pipeline.CHRS
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - 2026 will bring pivotal data for innovative oncology assets and drive growth in a $29B market.CHRS
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Q3 revenue hit $70.8M, UDENYCA and LOQTORZI surged, and net loss narrowed sharply.CHRS
Q3 202416 Jan 2026 - UDENYCA sale funds debt reduction and accelerates LOQTORZI's position as NPC standard of care.CHRS
Status Update12 Jan 2026